For the majority of companies who aren't shorted a
Post# of 153940
(Total Views: 494)
Posted On: 05/09/2022 7:40:46 PM
Re: Evil Rabbit #123000
For the majority of companies who aren't shorted as heavily as we are, the data would have been released.
We must be under NDA, the terms of which must be very good. Therefore, management is willing to raise money at current PPS.
The suitor is for NASH and the NDA concerns NASH, so of course it is under wraps and only known to CytoDyn and suitor.
CytoDyn has learned from past failures. Nader was all about puffing things up only to be met the next day with a falling share price. Even wonderful news was met the next day with strong short attacks.
Why should anything be different? The beautiful NASH 700 data which we all know is coming, and will be here in June on that poster date, would only be released early by CytoDyn if the NDA done away with and the suitor too may be revealed. Without disclosing the suitor and the terms of the deal, the NASH 700 data will only be met with a modest 25% upswing and then shorted day after day to bring it back down. unless, CytoDyn mentions the fact that discussions may be made allowable in the next few days, weeks, months regarding the suitor. Then, that may allow the shorts to relent a bit.
We are not dealing with phase 3 trial data which would be far more significant. We are moving along on a shoe string and management is being very careful. There are no more second chances.
We must be under NDA, the terms of which must be very good. Therefore, management is willing to raise money at current PPS.
The suitor is for NASH and the NDA concerns NASH, so of course it is under wraps and only known to CytoDyn and suitor.
CytoDyn has learned from past failures. Nader was all about puffing things up only to be met the next day with a falling share price. Even wonderful news was met the next day with strong short attacks.
Why should anything be different? The beautiful NASH 700 data which we all know is coming, and will be here in June on that poster date, would only be released early by CytoDyn if the NDA done away with and the suitor too may be revealed. Without disclosing the suitor and the terms of the deal, the NASH 700 data will only be met with a modest 25% upswing and then shorted day after day to bring it back down. unless, CytoDyn mentions the fact that discussions may be made allowable in the next few days, weeks, months regarding the suitor. Then, that may allow the shorts to relent a bit.
We are not dealing with phase 3 trial data which would be far more significant. We are moving along on a shoe string and management is being very careful. There are no more second chances.
(3)
(1)